Results 211 to 220 of about 413,499 (385)

Socio‐economic status and the effect of guideline‐directed medical therapy in the STRONG‐HF study

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Acute heart failure (AHF) impacts millions globally, with outcomes varying based on socio‐economic status (SES). Methods SES measured by annual household income, years of education and medical insurance coverage. Each patient's income and education level relative to the median or mean, respectively, in the country was calculated, and ...
Albertino Damasceno   +29 more
wiley   +1 more source

Natural Course of Peripartum Cardiomyopathy [PDF]

open access: bronze, 1971
John G. Demakis   +6 more
openalex   +1 more source

Septal Reduction Therapy for Obstructive Hypertrophic Cardiomyopathy: Volume Still Matters for Septal Myectomy

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Vincent Y. See, Libin Wang
doaj   +1 more source

Increased risk of cardiomyopathy in individuals with methamphetamine related disorders in Taiwan. [PDF]

open access: yesSci Rep
Yu PC   +10 more
europepmc   +1 more source

Implementation of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa‐HF Registry)

open access: yesESC Heart Failure, EarlyView.
Abstract Aims The last released European guidelines on the management of heart failure (HF) recommend in patients with chronic HF with reduced ejection fraction (HFrEF) a pharmacological approach based on four fundamental drugs to be rapidly implemented and then uptitrated to modify disease progression.
Stefania Paolillo   +62 more
wiley   +1 more source

Age at onset and clinical course of RBM20-mediated cardiomyopathy. [PDF]

open access: yesSci Rep
Garmany R   +7 more
europepmc   +1 more source

Trametinib alters contractility of paediatric Noonan syndrome‐associated hypertrophic myocardial tissue slices

open access: yesESC Heart Failure, EarlyView.
Abstract Aims No curative treatment is available for RASopathy‐associated childhood‐onset hypertrophic cardiomyopathy (RAS‐CM). Preclinical data and individual reports suggest a beneficial effect of small molecules targeting the RAS–mitogen‐activated protein (MAP) kinase (MAPK) pathway in severely affected RAS‐CM patients.
Jules Hamers   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy